Using knowledge gained through clinical research, our mission is to prevent T1D and stop disease progression by preserving insulin production before and after diagnosis.
An international commitment to stop T1D
The TrialNet family is made up of physicians, scientists and healthcare teams at the forefront of type 1 diabetes research.
Many of us have a personal connection with type 1 diabetes (T1D), fueling our passion to help families affected by T1D. We’re also the largest international network of T1D researchers in the world.
We offer free T1D risk screening, called the Pathway to Prevention Study, to relatives of people with T1D to detect the disease in its earliest stage—often years before symptoms appear. With the help of thousands of volunteers participating in our clinical studies, we are learning more about how T1D progresses. From that knowledge, we can test new ways to maintain insulin production before and after diagnosis.
Our goal: find a way to prevent type 1 diabetes.
TrialNet was established in response to the Surgeon General's Report Healthy People in 2000.
TrialNet was established in response to the Surgeon General's Report Healthy People 2000. This report identified diabetes as a national health objective for the United States. In response, Congress created the Diabetes Research Working Group (DRWG) to develop a plan of action for diabetes research. One of their recommendations was to conduct additional research studies toward preventing type 1 diabetes.
As a result, the Diabetes Prevention Trial of Type 1 (DPT-1) was launched in 1994. DPT-1 was a large multicenter, randomized, controlled clinical trial to investigate the possibility of delaying or even preventing clinical onset of T1D with daily doses of insulin in individuals at risk for the disease. When the trial concluded, TrialNet was created to continue this important work, and find a way to prevent the disease.
